/24-7PressRelease/ - MONROVIA, CA, August 09, 2008 - Dr. Ashraf Hanna, Vice President of Alliance Management and Portfolio Planning at Genentech in San Francisco, CA will present at the Plenary Keynote session at GTCbio's 4th Modern Drug Discovery and Development Summit on October 15-17, 2008 in La Jolla, CA.
Dr. Hanna will present on The Cost and Benefit of Portfolio Innovation. In his presentation, Dr. Hanna will review historical drug development costs and its impact on society. He will assess the current environment for drug development and answer such questions as "Is innovation in the pharmaceutical industry threatened?" Finally, Dr. Hanna will outline possible trends to consider that we can impact to maintain a focus on scientific progress and improved treatments for patients.
The 4th Modern Drug Discovery & Development Summit features over 150 speakers participating in 6 concurrent conferences, 6 mini sessions and 3 short symposia. Other plenary speakers include John Doll, Commissioner of Patents at the US Patent & Trademark Office, David Nicholson, SVP of Global Project Management at Schering Plough, Keith James, SVP & Site Head at Pfizer La Jolla, Johan Luthman, Global Head of Exploratory Medicine Neurology at MerckSerono and Sandy Macrae, VP of Business Development at GlaxoSmithKline. The 6 tracks will cover Biological Therapeutics, Translational Medicine, Drug Design & Lead Optimization, Emerging Targets &, Pharmacokinetics & Pharmacodynamics and Partnering, Licensing & Outsourcing. For more information, visit http://www.gtcbio.com.
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com
# # #
- and, antibodies, cell, cells, cns, development, discovery, drug, drugs, licensing, m3d, medicine, metabolic, modern, nervous, partnering, pharmacodynamics, pharmacogenomics, pharmacokinetics, regenerative, research, stem, system, translational
Read more Press Releases from Rania Hafez:- Michael Karin, Professor at UCSD to Give Keynote Speech at 7th Cytokines & Inflammation Conference
- GTCbio Announces its 7th Annual Cytokines & Inflammation Conference
- Samir Hanash, Program Head at the Fred Hutchinson Cancer Research Center to Give Keynote Speech at GTCbio's 2nd Oncology Biomarkers Conference on January 19-20 in Miami, Florida
- GTCbio Announces its 2nd Annual Oncology Biomarkers Conference
- Michael Shih, Director of Business Development at Eisai Inc. and Deepa Talpade, Director of Global Licensing & Strategic Alliances at Schering Plough to Give Joint Featured Presentation at GTCbio's CNS Diseases Partnering & Deal-Making Summit on Dec. 1-2, 2008 in Boston, MA
- GTCBIO ANNOUNCES ITS INAUGURAL CNS DISEASES PARTNERING & DEAL-MAKING SUMMIT
- Johan Luthman, Global Head of Exploratory Medicine Neurology at MerckSerono to Give Plenary Keynote Address at 4th Modern Drug Discovery & Development Summit (Oct. 15-17, 2008 - San Diego, CA)
- Herbert Fritsche, Professor and Chief of Clinical Chemistry at MD Anderson Cancer Center to Give Keynote Presentation at GTCbio's Biomarker Discovery Europe Conference on October 2-3, 2008 in Dublin, Ireland
- Mike Romanos, Vice President of Discovery Technologies at GlaxoSmithKline to Give Keynote Presentation at GTCbio's Biomarker Discovery Europe Conference on October 2-3, 2008 in Dublin, Ireland
- Sharath Hegde, Vice President at Theravance to Give Featured Presentation at GTCbio's Bugs & Drugs Conference on September 22-23, 2008 in San Diego, CA
Other Press Release Headlines:
